statin

Overview

Statins (formally classified as 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, or HMG-CoA reductase inhibitors) are a class of lipid-lowering agents that competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for endogenous cholesterol biosynthesis. By blocking this enzymatic step, statins reduce hepatic cholesterol production and upregulate low-density lipoprotein (LDL) receptor expression on hepatocytes, thereby lowering circulating LDL cholesterol and reducing the risk of atherosclerotic cardiovascular disease. First approved for clinical use in the late 1980s, statins have become among the most widely prescribed drugs globally and are considered a cornerstone of primary and secondary cardiovascular prevention. Common members of this drug class include Atorvastatin and simvastatin, which differ in their lipophilicity, potency, and metabolic profiles — properties that influence both their efficacy and their safety signatures across organ systems.

Beyond their canonical cholesterol-lowering mechanism, statins exhibit a range of pleiotropic effects — including anti-inflammatory, immunomodulatory, and antioxidant activities — that are only partially explained by reductions in LDL cholesterol or modulation of the mevalonate pathway. These additional biological actions have positioned statins as candidate therapies or adjuncts in a growing number of disease contexts beyond cardiovascular disease, including oncology, liver disease, neurological conditions, and inflammatory disorders. Their broad biological footprint, however, also underlies a spectrum of adverse effects and drug interactions that continue to be characterized in large-scale clinical and genetic studies.

Focus of Latest Publications

Recent publications on statin have focused on its use in combination strategies, prevention settings, and potential safety or adverse-effect signals across diverse clinical contexts. In acute cerebrovascular disease, a randomized trial examined whether immediate intensive statin therapy adds benefit to dual antiplatelet treatment with clopidogrel and aspirin in patients with mild ischemic stroke or transient ischemic attack, reflecting ongoing interest in early, synergistic secondary prevention. Another randomized controlled trial evaluated statin plus dapagliflozin, a sodium glucose cotransporter-2 inhibitor, in ischemic heart disease with heart failure, aiming to explore possible combined effects on ejection fraction and laboratory markers.

Several studies addressed statins in long-term prevention and real-world effectiveness. A target trial emulation investigated cardiovascular outcomes and safety of statin therapy for primary prevention in adults aged 75 years or older with type 2 diabetes, a population underrepresented in randomized trials. In liver disease, a national retrospective cohort study assessed whether long-term statin use reduced hepatocellular carcinoma risk in metabolic dysfunction–associated steatotic liver disease, reporting a lower HCC risk with statin exposure and suggesting a protective association regardless of MASLD status. Statin use was also examined in advanced prostate cancer through a secondary analysis of the SPARTAN trial, focusing on survival outcomes during apalutamide treatment.

Other recent work has explored adherence, pharmacogenetics, and potential adverse effects. A multicentre randomized trial protocol, AdLip, was designed to test a health coach-supported mobile health intervention to improve adherence to statins in adults with hyperlipidaemia. A separate study evaluated apolipoprotein E and SLCO1B1 polymorphisms for their impact on statin efficacy and safety in dyslipidemic patients. In the safety domain, an NHANES and Mendelian randomization analysis found no significant association between statin use and diabetic peripheral neuropathy in observational data, while genetic proxy analyses suggested possible associations between inhibition of HMGCR and increased odds of diabetic peripheral neuropathy and trigeminal neuralgia. Finally, an international vignette study of older adults examined preferences toward deprescribing statins, emphasizing the role of patient beliefs and shared decision-making, and a triple-blinded trial tested simvastatin for prevention of recurrent pancreatitis, reflecting continued investigation of statins beyond lipid lowering.

Key Publications

• NEWJun Dual Antiplatelet Therapy and Immediate Intensive Statin in Mild Ischemic Stroke: A Randomized Trial. (Neurology, 2026, PMID 42348803): "The aim of this study was to investigate the effect of combining clopidogrel-aspirin and immediate intensive statin in patients with acute mild ischemic stroke or transient ischemic attack (TIA)."
• NEWJun Cardiovascular outcomes and safety associated with statin therapy for primary prevention in older adults with type 2 diabetes: A target trial emulation study. (PLoS medicine, 2026, PMID 42340940): "We aimed to determine the effectiveness and safety of statin therapy for primary CVD prevention among type 2 diabetes patients aged ≥75 years."
• May The Effect of the combination therapy of statin and dapagliflozin, a selective inhibitor of sodium_glucose Co-transporter type 2, in the treatment of Ischemic heart disease with heart failure: A randomized controlled trial. (European journal of clinical pharmacology, 2026, PMID 42133048): "Although both are well known for diminishing cardiovascular risk and heart failure-related mortality, the possible synergistic benefits of using them together have not been thoroughly investigated."
• May Health coach-supported mobile health intervention to improve adherence to lipid-lowering medications (AdLip): Design and rationale of a multicentre randomized controlled trial protocol. (PloS one, 2026, PMID 42085423): "We aim to evaluate the effectiveness of a human coach-supported digital personal health assistant (mobile health app) intervention in improving adherence to statins in adults with hyperlipidaemia."
• May Statin Use and Neuropathic Pain: Evidence from NHANES and Mendelian Randomization Analyses. (Molecular neurobiology, 2026, PMID 42081017): "Emerging evidence suggests that lipid-lowering drugs may influence the development or progression of NP."
• Mar Effects of apolipoprotein E and solute carrier organic anion transporter family member 1B1 gene polymorphisms on statin efficacy and safety in dyslipidemic patients. (Pharmacogenetics and genomics, 2026, PMID 41861156): "To investigate the distribution of the apolipoprotein E (ApoE) and solute carrier organic anion transporter family member 1B1 (SLCO1B1) polymorphisms in dyslipidemia patients and their impact on statin efficacy and safety."
• Apr Mitochondrial dysfunction and applications of mitochondrial-targeted delivery systems in atherosclerosis. (Drug delivery, 2026, PMID 41668545): "Although conventional therapies such as statins and anti-inflammatory drugs can partially mitigate symptoms, they do not directly correct mitochondrial abnormalities and are often limited by systemic side effects."
• May Statin Use and Risk of Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease: A National Retrospective Cohort Study. (Cancer prevention research (Philadelphia, Pa.), 2026, PMID 41652814): "Statins may reduce hepatocellular carcinoma (HCC) risk regardless of metabolic dysfunction-associated steatotic liver disease (MASLD) status."
• May Statin use and outcomes in advanced prostate cancer:Secondary analysis of the SPARTAN trial. (Urologic oncology, 2026, PMID 41654482): "To assess the impact of statin use on survival outcomes in the phase III SPARTAN trial of apalutamide for nonmetastatic castration-resistant prostate cancer."
• May Trust first, concerns second: An international vignette study of older adults' preferences towards deprescribing statins. (British journal of clinical pharmacology, 2026, PMID 41531191): "This study investigated the attitudes and beliefs of older adults towards deprescribing statins in Australia, the United Kingdom and the United States, using an online, vignette-based study."